Knowing Is Not Enough, We Must Apply: SG...

Master the latest evidence-based meds and dual therapies to help your patients quit for good. Credit available for this activity expires: 06/25/2027 Earn Credit / Learning Objectives & Disclosures: https://www.staging.medscape.org/viewarticle/pharmacological-and-combination-inter ... Show More

Is sustained hemostatic normalization achievable across all hemophilia A patients? Examine the evidence behind today's therapeutic advances. Credit available for this activity expires: 6/26/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/n ... Show More

Drs García-Pavia and Sperry break down the top 5 mistakes in transthyretin amyloid cardiomyopathy (ATTR-CM) management and share clinical solutions for earlier, optimized patient care. Credit available for this activity expires: 6/25/27 Earn Credit / Learning Objectives & Disclos ... Show More

Drs Sparks and Neuen discuss the proper use of SGLT2 inhibitors to prevent chronic kidney disease, including how to start them and monitor them and their possible side effects. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/vie ... Show More

CardioNerds Drs. Jason Feinman, Gurleen Kaur, and Rick Ferraro discuss the implementation of SGLT inhibitors in clinical practice with Dr. Alison Bailey. Notes were drafted by Dr. Jason Feinman. In this episode, we discuss the implementation of SGLTi in clinical practice scenario ... Show More

<p>SGLT2 inhibitors, publishing choices, second and third order effects of interventions, decision support, and patient selection for preventive procedures are the topics John Mandrola, MD, discusses in this week's podcast.</p> <p><em>This podcast is intended for healthcare profe ... Show More

Dr. Centor discusses the indications for prescribing sodium-glucose cotransporter-2 inhibitors for patients with heart failure with observed ejection fraction with Dr. Sarah Adie. 

We are back with part 2 of our diabetes saga. Today, we discuss treatment goals and different oral agents that can be used to treat type 2 diabetes. Check out the website for the Rosh Review question of the week. Twitter: @creogsovercoff1 Instagram: @creogsovercoffee Facebook: ww ... Show More

Have you noticed that your patients are being prescribed SGLT-2 inhibitors, even if they don't have diabetes? If your patient asked, would you be able to explain why they are taking an SGLT-2 inhibitor?Listen in to learn about how this new and fascinating class of medication that ... Show More

Join experts Drs Matthew Sparks and James Matthew Luther as they discuss how and why they're using mineralocorticoid receptor antagonists to treat patients with diabetic kidney disease in their practice. Relevant disclosures can be found with the episode show notes on Medscape (h ... Show More

CardioNerds Dr. Rick Ferraro, Dr. Gurleen Kaur, and Dr. Maryam Barkhordarian discuss the evidence and data supporting SGLT inhibition for cardiovascular and kidney health outcomes with expert faculty Dr. Muthu Vaduganathan. They discuss the role of SGLT inhibitors in different po ... Show More

Join host Dr. Peter Lin (Canadian Heart Research Centre, Canada) in conversation with Dr. Joel Topf (Oakland University, William Beaumont School of Medicine, USA) as they discuss how to combat CKD progression and the role of non-pharmacological vs pharmacological interventions. T ... Show More

Listen in as experts discuss the latest updates in AFib management. Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/963752?src=mkm_podcast_addon_963752